Pharmacovigilance
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| Arava® -leflunomide |
Risk of serious birth defects when administered during pregnancy<strong> </strong><strong></strong> |
||
| Methotrexate "Ebewe” |
Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE &quot;EBEWE “ for autoimmune diseases |
||
| Roaccutne |
Roaccutne (isotretinoin): An update on neuropsychiatric disorders. |
||
| soliqua (lixisenatide /insuline glargin) soliqua |
(lixisenatide /insuline glargin): Important information on dosing. |
||
| Gilenya (fingolimod) |
Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception. |
||
| Advaquin ( levofloxacin) |
Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection. |
||
| Darzalex (Daratumumab) |
Darzalex (Daratumumab): New identified risk of hepatitis B reactivation. |
||
| Lemtrada® Alemtuzumab |
Alemtuzumab (Lemtrada): New safety information. |
||
| Apixaban, Edoxaban, Dabigatran and Rivaroxaban |
Direct Healthcare Professional Communication (DHPC) for the Direct Oral Anticoagulants (DOACs) Apixaban, Edoxaban, Dabigatran and Rivaroxaban. |
||
| blinatumomab |
Blincyto (pembrolizumab): Risk of Medication Errors and Benzyl alcohol toxicity. |
